Adaptive Biotechnologies to Present at the BofA Securities 2020 Healthcare Conference
Adaptive Biotechnologies (Nasdaq: ADPT) announced its participation in the BofA Securities Virtual Healthcare Conference on May 6, 2020.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Adaptive Biotechnologies (Nasdaq: ADPT) announced its participation in the BofA Securities Virtual Healthcare Conference on May 6, 2020. Management will present on May 13 at 12:00 p.m. Pacific Time / 3:00 p.m. Eastern Time. A live and archived webcast of the presentation will be accessible on the company’s website. Adaptive Biotechnologies focuses on utilizing the adaptive immune system for clinical applications in diagnosing and treating diseases, with a pipeline that includes products for cancer, autoimmune diseases, and infections.
Details
News Market Reaction – ADPT
The recorded move for ADPT in the trading session of this news was +2.54%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SEATTLE, May 06, 2020 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating in the upcoming BofA Securities Virtual Healthcare Conference.
Adaptive Biotechnologies’ management is scheduled to present on Wednesday, May 13th at 12:00 p.m. Pactific Time / 3:00 p.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation on the “Investors” section of the company website at: www.adaptivebiotech.com.
About Adaptive Biotechnologies
Adaptive Biotechnologies is a commercial-stage biotech company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature’s most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Our proprietary immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed to develop products in life sciences research, clinical diagnostics, and drug discovery. We have two commercial products, and a robust clinical pipeline to diagnose, monitor and enable the treatment of diseases such as cancer, autoimmune conditions and infectious diseases. Our goal is to develop and commercialize immune-driven clinical products tailored to each individual patient. For more information, please visit adaptivebiotech.com and follow us on www.twitter.com/adaptivebiotech.
Investor Contact:
Carrie Mendivil
investors@adaptivebiotech.com
Media Contact:
Beth Keshishian
media@adaptivebiotech.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.